ME-ITech Emerges as a Dark Horse in High-Throughput Oligo Synthesis, Solving Key Challenges in Length, Throughput, and Error Rate

In recent years, the oligonucleotide synthesis (Oligo Synthesis) industry has witnessed rapid growth, with technological advancements and service innovations continuously driving its development, while market size and application fields keep expanding. In this fast-growing sector, ME Instruments, a dark horse, has achieved breakthroughs in DNA synthesis technology through years of dedicated research and continuous innovation, surging ahead in the Oligo Synthesis industry.

ME Instruments Officially Launches Next-Generation High-Throughput Oligo Synthesis ServiceRecently, ME Instruments officially launched its next-generation high-throughput oligo synthesis service. Characterized by clearly defined low synthesis costs, extended synthesis length, high efficiency, high accuracy, high flexibility, high stability, and short turnaround times, this service introduces a groundbreaking cost-effective and efficiency-enhancing solution to the life sciences sector, including molecular biology, gene therapy, diagnostics, and drug development.

Oligonucleotides, or oligos, are short chains of nucleotides in which multiple adjacent nucleotide residues are linked by phosphodiester bonds. They serve as the foundation for applications in various fields, including gene synthesis, DNA sequencing, gene editing, gene therapy, molecular biology, diagnostics, and drug development.

The chemical synthesis of oligonucleotides began in the late 1940s. In 1955, Todd’s laboratory at the University of Cambridge successfully synthesized simple dimeric oligonucleotides using a chemical method for the first time, earning the Nobel Prize in 1957. In the 1980s, Marvin Caruthers’ research group developed the solid-phase phosphoramidite four-step method, now widely used and also known as column-based synthesis.

After years of development, oligonucleotide synthesis technology has evolved from early chemical synthesis to automated, high-throughput methods, and now to ultra-high-throughput and high-precision synthesis technologies.Oligonucleotide synthesis is playing an increasingly important role in biomedical research and applications, demonstrating significant potential and importance. According to data from RNAScript, the global market for oligonucleotide synthesis is projected to grow from $6.3 billion in 2021 to over $14.1 billion in 2026, representing a compound annual growth rate (CAGR) of 17.6% during this period.

Despite the industry’s rapid growth, large market size, and diverse application scenarios, the currently widely adopted column-based synthesis method is limited by incomplete chemical reactions at each step and the occurrence of side reactions (such as depurination during deprotection). As the oligonucleotide chain length increases, synthesis efficiency decreases and error rates rise, significantly restricting both the achievable synthesis length and quality.

Therefore, taking all factors into consideration, there is a need in the industry for a new synthesis method to achieve oligonucleotide (Oligo) synthesis with high yield, high accuracy, high flexibility, and high stability, while ensuring low cost.

By pinpointing industry pain points and market demands, the ME Instruments team leverages an internationally leading technology platform and integrates precision instrument manufacturing processes to rapidly translate cutting-edge scientific achievements into high-standard, high-quality practical applications.ME Instruments’ newly launched high-throughput oligo synthesis service not only significantly reduces synthesis costs and addresses key industry pain points, but also offers five distinct competitive advantages:

High Synthesis Efficiency:ME Instruments’ high-throughput oligo synthesis service ensures high synthesis efficiency, enabling the synthesis of up to 1.2 million sequences per run (with a typical capacity of one million), with sequence lengths reaching 180 nt, thereby significantly reducing synthesis costs.

High Accuracy:Under the premise of meeting the requirements for high-throughput synthesis of long-chain oligonucleotides, ME Instruments leverages advanced synthesis and purification technologies to ensure product quality. Its oligonucleotide pools achieve complete coverage of target regions with highly uniform characteristics and an error rate as low as 0.2%.

High Flexibility:To ensure that every customer’s needs are met to the greatest extent, ME Instruments’ new generation of high-throughput oligo synthesis products is now available for pre-order, offering end-to-end services from customized requirements to delivery. Additionally, customers who pre-order during the promotional period will enjoy priority service and special offers.

Figure 1. The high-throughput oligo synthesis workflow can be flexibly customized according to customer needs. Image source: ME Instruments

High Stability: ME Instruments' synthesis platform, subjected to rigorous quality control and integrated with precision instrument manufacturing processes, ensures product stability and reliability.

Shorter Cycle:While ensuring quality across all aspects, ME Instruments offers a 48-hour synthesis service to meet customer delivery timelines, thereby shortening clients’ R&D and production cycles and enhancing their competitiveness in the market.

Below are partial performance data for ME Instruments’ new-generation high-throughput oligo synthesis service:

Figure 2. Quality control of the oligonucleotide pool. Image source: ME Instruments

Figures A–C present the quality control data for an oligonucleotide pool comprising 3,000 oligos, each with a synthesized length of 135 nt. The synthesized oligonucleotide pool was subjected to high-throughput sequencing analysis after amplification. A. Coverage abundance of the 3,000 sequences; B. Uniformity of the target sequences; C. Synthesis error rate of the target sequences. Figure D presents the quality control data for an oligonucleotide pool comprising 2,700 oligos, each with a synthesized length of 140 nt, which exhibited high uniformity across different GC content regions after amplification.

Figure 3. Performance of the synthesized panel. Image source: ME Instruments

42.5 kb and 2.6 Mb panels were used for capture, with data demonstrating high uniformity across different GC regions.

The successful launch of the new generation of high-throughput oligo synthesis services would not have been possible without the years of dedicated research and development by the ME Instruments team.

ME Instruments, founded in 2018 by Professor Jingyue Ju, Director of the Center for Genome Technology at Columbia University and a renowned scientist in the field of gene sequencing, together with Dr. Jian Wu and others, is a high-tech company specializing in the research and development, translation, manufacturing, and application of gene sequencing analysis platforms and related technologies. The company encompasses four major business segments: high-end gene sequencing instruments, molecular enzymology products, high-throughput DNA synthesis, and chemical synthesis services.

ME Instruments has demonstrated robust technical capabilities in the field of high-throughput oligonucleotide synthesis, leading industry development through its independently developed innovative platforms and technological breakthroughs. Currently, the company holds multiple invention patents and utility model patents that cover key segments of the nucleic acid synthesis technology chain. This service is capable of meeting multi-level demands ranging from scientific research to industrial-scale production.

Currently, ME Instruments has established a global footprint spanning “Columbia University (USA) – Shenzhen R&D Center – Beijing R&D Center – Jiangsu Large-Scale Production Base.” The company has built a Class 10,000 chip production workshop, an enzyme engineering laboratory, a nucleic acid synthesis laboratory, a chemical synthesis laboratory, and integrated system assembly and testing R&D laboratories, thereby establishing fully self-developed platforms for R&D and production.

Bolstered by the founding team’s technical expertise, global strategic layout, and commercialization capabilities for its flagship products, ME Instruments is poised to introduce more cutting-edge technologies and comprehensive solutions to the life sciences sector, while steadily expanding its presence in the global market. As a key branch of biological sciences, the oligonucleotide (oligo) synthesis industry will also benefit from ME Instruments’ dedicated R&D efforts, ushering in more efficient and cost-effective synthesis services that drive revolutionary advancements in disease diagnosis, treatment, and biopharmaceuticals.

To meet customer demands, ME Instruments’ new-generation high-throughput oligo synthesis products are now available for pre-order. We look forward to collaborating with you to advance scientific research and healthcare. Pre-order now to enjoy priority service and exclusive offers.

Company | ME Instruments Inc.

Website | www.me-itech.com

Email | mingyi@me-itech.com

Address | 1st Floor, Building F, International Pharmaceutical Innovation Industrial Park, No. 28 Yuehu Road, Economic and Technological Development Zone, Lianyungang Area, China (Jiangsu) Pilot Free Trade Zone

Room 321, Building No. 2, Huahan Technology Industrial Park, No. 19 Lanjin 4th Road, Heping Community, Pingshan Subdistrict, Pingshan District, Shenzhen

Business Contact Mobile Number | 132 6315 0689

References:
“Songhe Report: Industry Research on DNA Synthesis Technology”
【Research Essentials】Understanding Oligo Synthesis in One Article